My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
November 2017
POLICY AND ADVOCACY
IDSA Remains Committed to Fighting Antimicrobial Resistance

IDSA continues working to advance domestic and global policies to address antimicrobial resistance (AMR). Key recent activities include:

Wellcome Trust Global Call to Action:

IDSA Treasurer Helen Boucher, MD, FIDSA, served on a panel in Berlin, Germany in October about measuring success in addressing AMR globally, in which she spoke about the role of health care providers. IDSA Clinical Affairs Committee member Javeed Siddiqui, MD, discussed how telemedicine can allow ID specialists to support the implementation of stewardship globally.

Keynote at World AMR Congress:

IDSA then-President William Powderly, MD, FIDSA, joined the president of the American Society for Microbiology at the World AMR Congress in September for a joint keynote in which he highlighted IDSA’s AMR policy and advocacy efforts and the leading role of ID physicians in implementing antimicrobial stewardship.

WHO Global AMR Activities:

IDSA submitted comments to the World Health Organization (WHO) Interagency Coordination Group (IACG) for AMR, including recommending that WHO and IAGG:

  • advance economic incentives for new antimicrobial drugs, diagnostics and vaccines;
  • promote research that leads to improved use of existing antibiotics;
  • secure an expert infectious diseases workforce to address AMR;
  • coordinate AMR and TB activities; create a mechanism to facilitate collaboration and sharing of resources and knowledge;
  • facilitate multinational research networks; provide nuanced guidance, tools and training on stewardship that are geared towards the constraints and concerns of individual countries; and
  • develop global goals with quantifiable targets, specific timelines and benchmarks for progress.

IDSA offered to provide forums for WHO and the IACG to engage with ID clinicians and scientists and share ID expertise with other countries. The Society also offered feedback on indicators that would be feasible and meaningful for assessing progress on AMR.

Advancing Antibiotic Incentives:

IDSA attended the meeting of DRIVE-AB—a consortium spearheaded by the European Union’s Innovative Medicines Initiative to develop proposals for economic incentives to spur the development of urgently needed new antimicrobial drugs. DRIVE-AB’s recommendations are well-aligned with IDSA’s policies, calling for investment in push incentives (e.g., grants and tax credits that provide support during research and development) and pull incentives (i.e., rewards provided after a new antimicrobial drug is brought to market). DRIVE-AB specifically calls for the development of a generous market entry reward for new antimicrobials that target pathogens identified as priorities by WHO. Under such a proposal, companies receiving the reward would also make commitments regarding stewardship and access. IDSA is convening a working group through our Stakeholder Forum on Antimicrobial Resistance (S-FAR) to develop a complementary market entry reward proposal for the US.

S-FAR, PACCARB and Joint Commission:

IDSA held its annual S-FAR meeting this fall, during which the group strategized about advocacy for federal and global AMR funding and new ways to engage patients in AMR policy efforts. The group also met with staff from the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) and received an update from the Joint Commission (JC) about implementation of its stewardship requirement, which took effect earlier this year.

The JC has begun surveying hospitals to review their stewardship programs. According to initial findings, 14 out of 211 hospitals were cited for one or more deficiencies in their antimicrobial stewardship programs, including:

  • Antimicrobial stewardship not a leadership priority (1)
  • No evidence of a multidisciplinary team approach (3)
  • Program/policy did not include all of the Centers for Disease Control and Prevention’s core elements (3)
  • Education not provided to staff and/or Licensed Independent Practioner (5)
  • Education not provided to patient/family (2)


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
HIVMA Releases Guideline on HIV and Chronic Pain
ACIP Makes New Recommendations on Shingles, Mumps Vaccines
Weighing in on HHS Report on Vaccine Innovation
Updates on NIHís Next Generation Researchers Initiative
CLINICAL PRACTICE MANAGEMENT
IDSA to UHC: Donít Deny Payment for Cognitive Services
Reimbursement for Telemedicine Could Get Easier
How to Stay Abreast of CMSís Quality Payment Program
POLICY AND ADVOCACY
IDSA Remains Committed to Fighting Antimicrobial Resistance
FY2018 Funding News
IDSA Continues to Press for Diagnostics Reimbursement
FDA Public Workshop on Antimicrobial Susceptibility Tests
IDSA Member Testifies at New York State Hearing on Lyme Disease
GLOBAL HEALTH
Science Speaks Covers IDWeek, Union World Conference on Lung Health
Congressional Study Tour to CDC Global Health
EDUCATION AND RESOURCES
Fellowship in Stewardship and Resistance Receives CDC Funding
HIVMA Clinical Fellowship and Medical Students Program
PCORI Funding Announcement: Community-Acquired Pneumonia
FROM THE PRESIDENT
Maintaining Our Momentum
TOP STORIES
IDSA Launches Antimicrobial Stewardship Centers of Excellence Program
Updated Guideline on Infectious Diarrhea Now Available
IDWeek 2017 Recap
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.